期刊文献+
共找到39,921篇文章
< 1 2 250 >
每页显示 20 50 100
The Qilin Delivers a Jade Tablet to Confucius’Mother
1
《China Today》 2026年第2期69-69,共1页
Confucius’imminent birth is heralded by the appearance of the qilin.The mythical one-horned animal came to his mother at the door and cast out of its mouth a jade tablet bearing an inscription saying that she would g... Confucius’imminent birth is heralded by the appearance of the qilin.The mythical one-horned animal came to his mother at the door and cast out of its mouth a jade tablet bearing an inscription saying that she would give birth to“the son of the refinement of water,and that he would succeed the Zhou Dynasty,but as a king without a throne(su wang).”Stunned,Yan Zhengzai–Confucius’mother–tied an embroidered ribbon around the horn of the qilin,and the animal stayed for two nights. 展开更多
关键词 qilin refinement water mythical animal CONFUCIUS jade tablet zhou dynasty INSCRIPTION imminent birth
在线阅读 下载PDF
Analysis of the Efficacy of Short-Term Intensive Continuous Subcutaneous Insulin Infusion (CSII) Combined with Ganagliflozin Proline Tablets in Elderly Patients with Type 2 Diabetes Mellitus
2
作者 Hui Dai 《Journal of Clinical and Nursing Research》 2026年第2期286-291,共6页
Objective:To investigate the effects of switching to either Prandilin 25R monotherapy or Prandilin 25R combined with ganagliflozin proline tablets after short-term intensive continuous subcutaneous insulin infusion du... Objective:To investigate the effects of switching to either Prandilin 25R monotherapy or Prandilin 25R combined with ganagliflozin proline tablets after short-term intensive continuous subcutaneous insulin infusion during hospitalization in elderly patients with type 2 diabetes mellitus on glycemic control,glycometabolic indicators,and cardiovascular risk factors,and to evaluate the safety of the two regimens.Methods:A total of 78 elderly patients with type 2 diabetes mellitus admitted to our hospital from January 2025 to September 2025 were selected and randomly divided into a control group and an observation group,with 39 cases in each group.The control group received monotherapy with insulin lispro protamine recombinant injection(Prandilin 25R)after intensive continuous subcutaneous insulin infusion,while the observation group received Prandilin 25R combined with ganagliflozin proline tablets.Continuous glucose monitoring(CGM)was performed for 14 days during the intensive continuous subcutaneous insulin infusion therapy phase in the hospital,followed by routine fingertip blood glucose monitoring after 14 days.Glycemic control indicators,glycometabolic indicators,and the incidence of adverse reactions were compared between the two groups.Results:After treatment,the mean amplitude of glycemic excursions and the 24-hour blood glucose standard deviation were significantly lower in the observation group than in the control group,while the time spent within the target blood glucose range was significantly higher(p<0.05).The levels of glycated hemoglobin,fasting blood glucose,and 2-hour postprandial blood glucose were better in the observation group than in the control group;moreover,the body mass index,systolic blood pressure,and blood lipid levels improved more significantly in the observation group than in the control group(p<0.05).There was no statistically significant difference in the incidence of hypoglycemia between the two groups.Conclusion:Combination therapy with ganagliflozin proline tablets after short-term intensive continuous subcutaneous insulin infusion therapy can effectively improve glycemic variability in elderly patients with type 2 diabetes mellitus,with good safety.This suggests that ganagliflozin proline tablets have a hypoglycemic advantage in the combination regimen and possess high clinical promotional value. 展开更多
关键词 Type 2 diabetes mellitus Continuous subcutaneous insulin infusion Ganagliflozin proline tablets Glycemic variability
暂未订购
Integrated serum pharmacochemistry and network pharmacology validate Qiangli Dingxuan Tablets ameliorates metabolic hypertension via TLR4/MyD88/NF-κB pathway
3
作者 Jia-Yue Zhu Ying-Jie Dong +5 位作者 Ya-Wen Sun Min-Qiu Lin Fan Liu Jie Su Gui-Yuan Lv Su-Hong Chen 《Traditional Medicine Research》 2026年第8期1-14,共14页
Background:Modified Qiangli Dingxuan Tablets(ZYSJ)is an optimized formulation derived from the classic Chinese patent medicine Qiangli Dingxuan Tablet.It targets the pathological features associated with metabolic hyp... Background:Modified Qiangli Dingxuan Tablets(ZYSJ)is an optimized formulation derived from the classic Chinese patent medicine Qiangli Dingxuan Tablet.It targets the pathological features associated with metabolic hypertension(MH)and metabolic disorders,although its antihypertensive mechanism remains unclear.Methods:A rat model of metabolic hypertension was established using a high-sugar,high-fat diet combined with progressively increasing concentrations of ethanol.Blood pressure,serum lipids,inflammatory cytokines,and endothelial function markers were assessed.Serum pharmacochemistry combined with network pharmacology was employed to predict key targets and pathways,followed by in vivo validation using qRT-PCR,Western blotting,immunofluorescence,and immunohistochemistry.Results:ZYSJ significantly reduced blood pressure and serum lipid levels in model rats.Thirty absorbed bioactive components were identified.Mechanistic studies revealed that ZYSJ downregulated the TLR4/MyD88/NF-κB signaling pathway at both the mRNA and protein levels,upregulated endothelial nitric oxide synthase(eNOS)expression,and decreased the levels of inflammatory cytokines(TNF-α,IL-1β,IL-6),thereby improving vascular endothelial function.Conclusion:ZYSJ effectively lowers blood pressure and serum lipids in rats with metabolic hypertension.Its mechanism of action is closely associated with regulation of the TLR4/MyD88/NF-κB signaling pathway,improvement of vascular endothelial function,and alleviation of inflammation. 展开更多
关键词 metabolic hypertension Modified Qiangli Dingxuan tablets TLR4/MyD88/NF-κB signaling pathway serum-absorbed components herbal medicine
暂未订购
Efficacy and safety of Tripterygium wilfordii glycosides tablets combined with Western medicine for patients with rheumatic immune diseases
4
作者 Hang Shu Xiao-Yu Chen +2 位作者 Jie Zhao Pin Li Zhen Sun 《World Journal of Clinical Cases》 SCIE 2025年第6期14-23,共10页
BACKGROUND Rheumatic immune diseases are a group of chronic inflammatory diseases charac-terized by joint and systemic multi-organ involvement,including rheumatoid arthritis,systemic lupus erythematosus,and Sjogren’s... BACKGROUND Rheumatic immune diseases are a group of chronic inflammatory diseases charac-terized by joint and systemic multi-organ involvement,including rheumatoid arthritis,systemic lupus erythematosus,and Sjogren’s syndrome,among others.The pathogenesis of these diseases is related to the abnormal activation and regulatory imbalance of the immune system.The prevalence and morbidity of rheumatic immune diseases are high,imposing a significant burden on patients'quality of life and socio-economic costs.Currently,the treatment of rheumatic immune diseases mainly relies on Western medicine,such as non-steroidal anti-inflammatory drugs,glucocorticoids,disease-modifying antirheumatic drugs,and biologics.However,the therapeutic effects of Western medicine are not ideal,some patients poorly respond or are resistant to Western medicine,and long-term use often causes various adverse reactions.AIM To systematically evaluate the efficacy and safety of Tripterygium wilfordii gly-cosides tablets combined with Western medicine in the treatment of patients with rheumatic immune diseases.METHODS This study conducted a meta-analysis to systematically evaluate the efficacy and safety of Tripterygium wilfordii glycosides tablets combined with Western medicine for patients with rheumatic immune diseases.Chinese and English databases were searched for randomized controlled trials(RCTs)on the treatment of rheumatic immune diseases with Tripterygium wilfordii glycosides tablets combined with Western medicine.The quality of the included studies was assessed using the Cochrane risk of bias assessment tool.Meta-analysis was performed using RevMan 5.4 software.RESULTS The meta-analysis included 11 RCTs involving 1026 patients with rheumatic immune diseases.The combined treatment significantly reduced the risk of disease recurrence(relative risk=1.07,95%confidence interval:1.01-1.15,P<0.05)and showed no significant heterogeneity(I2=0%,P=0.53),indicating that Tripterygium wilfordii glycosides tablets combined with Western medicine is an effective method to reduce the possibility of postoperative recurrence in patients with rheumatic immune diseases.However,due to the limited number and quality of the studies included,these results should be interpreted with caution.CONCLUSION Tripterygium wilfordii glycosides tablets combined with Western medicine is an effective and safe treatment option for patients with rheumatic immune diseases and can be considered a clinical choice.However,more high-quality research is needed to validate this conclusion and provide more solid evidence for clinical practice. 展开更多
关键词 Rheumatic immune diseases Tripterygium wilfordii polyglycosides tablets Western medicine treatment Systematic review META-ANALYSIS
暂未订购
A Case Study of Heart Failure Resulting from Dilated Cardiomyopathy Treated with Sacubitril Valsartan Sodium Tablets in Combination with Qiliqiangxin Capsules
5
作者 Qiuwen FU Li XU 《Medicinal Plant》 2025年第3期75-79,共5页
This article presents a case study of a 20-year-old male patient diagnosed with dilated cardiomyopathy(DCM)(NYHA IV).This condition was diagnosed as"heart failure disease"(water overflowing due to yang defic... This article presents a case study of a 20-year-old male patient diagnosed with dilated cardiomyopathy(DCM)(NYHA IV).This condition was diagnosed as"heart failure disease"(water overflowing due to yang deficiency,intermingled phlegm and stasis)in traditional Chinese medicine(TCM).The treatment approach employed a combination of TCM and Western medicine.Western medicine involved the administration of sacubitril valsartan sodium tablets to inhibit ventricular remodeling,in conjunction with diuretics and cardiotonic agents.Initially,TCM utilized a static infusion of Shenfu injection,which was subsequently supplemented with Qiliqiangxin capsules to invigorate qi,warm yang,activate blood circulation,and promote diuresis.After a follow-up period of 3 years,the patient's ejection fraction(EF)improved from 23%to 51%,and the left ventricular end diastolic diameter(LVed)decreased from 68 to 52 mm,accompanied by a significant alleviation of symptoms.These findings indicate that the combined treatment of TCM and Western medicine can synergistically enhance cardiac function and impede the progression of the disease,thereby offering valuable insights for the optimal management of DCM. 展开更多
关键词 DILATED cardiomyopathy (DCM) Heart failure Sacubitril VALSARTAN SODIUM tabletS Qiliqiangxin capsules Chest TIGHTNESS Shortness of BREATH
暂未订购
Hypolipidemic effect and mechanism of Hedan tablet (荷丹片) based on network pharmacology
6
作者 HU Huiming WENG Jiajun +6 位作者 TANG Fangrui WANG Yaqi FAN Shengxian WANG Xuecheng CUI Can SHAO Feng ZHU Yanchen 《Journal of Traditional Chinese Medicine》 2025年第2期408-421,共14页
OBJECTIVE:To examine Hedan tablet(HDT,荷丹片)'s potential mechanisms in hyperlipidemic rats induced by a high-fat diet(HFD),as well as its regulatory effects and primary active constituents.METHODS:By using ultra-... OBJECTIVE:To examine Hedan tablet(HDT,荷丹片)'s potential mechanisms in hyperlipidemic rats induced by a high-fat diet(HFD),as well as its regulatory effects and primary active constituents.METHODS:By using ultra-performance liquid chromatography(UPLC)-quadrupole-time-of-flight(QTOF)-tandem mass spectrometry(MS/MS),the components of HDT that can enter the circulatory system were found,aiming to investigate its active constituents with pharmacological effects.Based on network pharmacology approaches,the relevant HDT targets in the therapy of hyperlipidemia were anticipated.The possible mechanism of HDT for hyperlipidemia treatment was verified by in-vivo experiments,and the main active components of HDT for hyperlipidemia treatment were analyzed via in-vitro experiments.RESULTS:UPLC-QTOF-MS/MS identified 30 components of HDT entering the circulatory system,primarily consisting of flavonoids,diterpenoids and alkaloids.The results of a network pharmacology study revealed that 30 active components mostly target 74 genes associated with hyperlipidemia.The primary active ingredients may include quercetin,kaempferol,and epicatechin,and the main gene targets may be tumor necrosis factor(TNF),interleukin-6(IL-6),interleukin 1 beta(IL-1β),etc.The results of animal experiments demonstrated that HDT can significantly regulate the blood lipid level in rats with HFD,improve the degree of inflammatory infiltration in rat liver cells,lower TNF-α,Creactive protein(CRP),IL-6,matrix metalloproteinase 9(MMP9) and malondialdehyde(MDA) levels while raising total superoxide dismutase(T-SOD) level.Meanwhile,HDT can considerably lower the expression of sterol regulatory element-binding transcription factor 2(SREBF2),3-hydroxy-3-methylglutaryl-CoA reductase(HMGCR),and MMP9 while significantly increasing the expression of peroxisome proliferator-activated receptor alpha(PPAR-α) and PPAR-γ.In vitro study confirmed that quercetin and kaempferol could reduce the levels of IL-6,IL1B,MMP9 and HMGCR in the high-fat model of hepatoma G2 cells.CONCLUSIONS:The mechanism by which HDT treats hyperlipidemia involves modification of the lipid metabolism targets such as downregulating SREBF2,HMGCR and MMP9,and upregulating PPAR-α and PPAR-γ,as well as anti-inflammatory and antioxidant actions.This study provides a pharmacological and biological rationale for the use of HDT in clinical hyperlipidemia management. 展开更多
关键词 HYPERLIPIDEMIA MECHANISM network pharmacology ultra-performance liquid chromatography-quadrupole-time-offlight-tandem mass spectrometry Hedan tablet
原文传递
Clinical Study on the Combination Therapy of Diosmin Tablets and Mayinglong Musk Hemorrhoids Ointment for Patients with Acute Hemorrhoids
7
作者 Quanchang Sun 《Journal of Clinical and Nursing Research》 2025年第6期286-292,共7页
Objective:To evaluate the clinical effect of combined therapy with Diosmin Tablets and Mayinglong Musk Hemorrhoids Ointment for patients with acute hemorrhoids.Methods:A total of 50 patients with acute hemorrhoids who... Objective:To evaluate the clinical effect of combined therapy with Diosmin Tablets and Mayinglong Musk Hemorrhoids Ointment for patients with acute hemorrhoids.Methods:A total of 50 patients with acute hemorrhoids who visited the hospital from January 2023 to January 2025 were selected as samples and randomly divided into two groups.Group A was treated with Diosmin Tablets combined with Mayinglong Musk Hemorrhoids Ointment,while Group B was treated with Mayinglong Musk Hemorrhoids Ointment only.The efficacy,wound recovery time,perianal pain score,hemorrhoid symptom score,and stress indicators were compared between the two groups.Results:The efficacy of Group A was higher than that of Group B(P<0.05).The postoperative perianal edema time and wound healing time in Group A were shorter than those in Group B,and the Visual Analog Scale(VAS)score was lower than that in Group B(P<0.05).The hemorrhoid symptom score in Group A was lower than that in Group B(P<0.05).The stress level in Group A was lower than that in Group B(P<0.05).Conclusion:The combination therapy of Diosmin Tablets and Mayinglong Musk Hemorrhoids Ointment for postoperative treatment of acute hemorrhoids can effectively relieve perianal pain,shorten the duration of hemorrhoids,and is highly feasible. 展开更多
关键词 Acute hemorrhoids Mayinglong musk hemorrhoids ointment Diosmin tablets EFFICACY
暂未订购
Effect of Bifidobacterium Triple Viable Bacteria Tablets on Neonatal Necrotizing Enterocolitis and Its Impact on Serum Factors of the Patients
8
作者 Xiaoyan Ding 《Journal of Clinical and Nursing Research》 2025年第8期292-297,共6页
Objective:To analyze the efficacy of Bifidobacterium triple viable bacteria tablets on neonatal necrotizing enterocolitis(NEC)and its impact on serum factors of the patients.Methods:From January 2021 to May 2025,88 ne... Objective:To analyze the efficacy of Bifidobacterium triple viable bacteria tablets on neonatal necrotizing enterocolitis(NEC)and its impact on serum factors of the patients.Methods:From January 2021 to May 2025,88 neonates with NEC admitted to our hospital were selected as study subjects.During the study,these 88 patients were evenly divided into two groups,namely the observation group and the control group,with 44 patients in each group based on the random number table method.In terms of treatment,the control group was treated with meropenem,while the observation group received additional treatment with Bifidobacterium triple viable bacteria powder based on the treatment plan of the control group.The clinical efficacy and differences in serum inflammatory factor levels between the two groups were compared.Results:The efficacy of the observation group(90.91%)was better than that of the control group(72.73%)(P<0.05).After treatment,the levels of C-reactive protein(CRP)and procalcitonin(PCT)in both groups decreased compared to those before treatment,and the values of the above indicators in the observation group were lower than those in the control group(P<0.05).Conclusion:Based on conventional treatment for NEC neonates,the use of Bifidobacterium triple viable bacteria tablets has significant efficacy and can effectively reduce serum inflammatory factor levels. 展开更多
关键词 Bifidobacterium triple viable bacteria tablets Necrotizing enterocolitis NEONATES Serum factors
暂未订购
Exploring the mechanism of Shenhua tablet(肾华片)alleviating renal injury by regulating macrophage glycolysis via hypoxia-inducible factor-1α/pyruvate kinase M2 signaling pathway in diabetic kidney disease mice
9
作者 CHEN Yuanchun JING Jiaxing +5 位作者 LI Qingmin ZHOU Xiaohong JIN Xiaofei GAO Weijuan CHEN Xiangmei YU Wentao 《Journal of Traditional Chinese Medicine》 2025年第3期528-537,共10页
OBJECTIVE:To investigate the impact of Shenhua tablet(肾华片,SHT)on renal macrophage polarization and renal injury in mice with diabetic kidney disease(DKD)and to explore the potential mechanism involving the hypoxia-... OBJECTIVE:To investigate the impact of Shenhua tablet(肾华片,SHT)on renal macrophage polarization and renal injury in mice with diabetic kidney disease(DKD)and to explore the potential mechanism involving the hypoxia-inducible factor-1α(HIF-1α)and pyruvate kinase M2(PKM2)signaling pathway,along with the glycolysis metabolism pathway.METHODS:The animals were divided into the following groups:Model,Control,dapagliflozin,SHT low-dose,SHT medium-dose,and SHT high-dose.We assessed 24-hour urine protein(24 h-UTP)levels,urinary albuminto-creatinine ratio,and regularly monitored fasting blood glucose during the treatment period.After treatment,we examined renal tissue structure,renal function(urea nitrogen,uric acid,creatinine,cystatin C,β2-microglobulin),and glycolysis in renal macrophages.Additionally,we observed macrophage polarization in renal tissue and measured inflammatory factors(tumor necrosis factor-α,interleukin-1β,interleukin-6,interleukin-10,monocyte chemoattractant protein-1)to assess the immunoinflammatory status of the renal tissue.Finally,we investigated the expression of the HIF-1α/PKM2 signaling pathway in macrophages to explore its role in the glycolysis process.RESULTS:SHT shows a beneficial effect in treating DKD by reducing 24 h-UTP,regulating blood glucose levels,improving renal tissue structure,protecting renal function,inhibiting macrophage glycolysis,reducing macrophage transformation to the M1 state,and suppressing the expression of the HIF-1α/PKM2 signaling pathway.CONCLUSION:SHT may exert renoprotective effects by inhibiting macrophage glycolysis via the HIF-1α/PKM2 signaling pathway.This inhibition decreases macrophage M1 polarization and reduces immunoinflammatory injury in the renal tissue of DKD mice. 展开更多
关键词 diabetic kidney disease MACROPHAGES GLYCOLYSIS hypoxia-inducible factor-1α pyruvate kinase M2 Shenhua tablet
原文传递
Clinical Efficacy and Mechanism of Qinjin Tablet in Treating Unstable Angina with Phlegm-Stasis Syndrome Based on the HDL-C/MMP-9 Signaling Axis
10
作者 Yuan WANG Jingru GAO Hongjun ZHU 《Medicinal Plant》 2025年第6期49-53,63,共6页
[Objectives]To explore the clinical efficacy of Qinjin Tablet in treating unstable angina with phlegm-stasis syndrome and preliminarily explore its intervention mechanism.[Methods]Sixty unstable angina patients with p... [Objectives]To explore the clinical efficacy of Qinjin Tablet in treating unstable angina with phlegm-stasis syndrome and preliminarily explore its intervention mechanism.[Methods]Sixty unstable angina patients with phlegm-stasis syndrome were randomly divided into a treatment group and a control group(30 each).The control group received standardized Western medicine treatment,while the treatment group also took Qinjin Tablet.After a 4-week treatment,comparisons were made on improvement of angina symptoms,TCM syndrome scores,blood stasis scores,reduction/cessation of short-acting anti-angina drugs,Seattle Angina Questionnaire(SAQ)scores,blood lipid levels,and matrix metalloproteinase-9(MMP-9)concentrations between the two groups.[Results]No statistical differences existed in baseline data like age,gender,and disease duration between the two groups(P>0.05).The treatment group showed significantly better efficacy than the control group in improving angina symptoms,TCM syndrome scores,blood stasis scores,and reduction or discontinuation of short-acting anti-anginal drugs(P<0.05).The SAQ score increase was more significant in the treatment group(P<0.05).The control group significantly reduced low-density lipoprotein cholesterol(LDL-C)(P<0.05),while the treatment group markedly increased high-density lipoprotein cholesterol(HDL-C)(P<0.05).Post-treatment,the treatment group had a marked reduction in serum MMP-9(P<0.05),with no significant change in the control group.[Conclusions]Qinjin Tablet can significantly alleviate clinical symptoms and improve quality of life in UA patients by modulating the HDL-C/MMP-9 signaling pathway. 展开更多
关键词 Qinjin tablet Unstable angina Phlegm-stasis interlocking syndrome High-density lipoprotein cholesterol Matrix metalloproteinase-9
暂未订购
Efficacy and Safety Study of Rasagiline Tablets in the Treatment of Parkinson’s Disease
11
作者 Lu Zhang Jin Xu +1 位作者 Ling Liu Haiyan Tang 《Journal of Clinical and Nursing Research》 2025年第11期344-349,共6页
Objective:To evaluate the efficacy and safety of rasagiline tablets in the treatment of Parkinson’s disease,in order to provide a more scientific basis for the application of the drug in Parkinson’s disease.Methods:... Objective:To evaluate the efficacy and safety of rasagiline tablets in the treatment of Parkinson’s disease,in order to provide a more scientific basis for the application of the drug in Parkinson’s disease.Methods:This study is a single-arm,prospective,observational study.The trial collected patients with primary Parkinson’s disease who met the inclusion and exclusion criteria after being assessed by the investigator to evaluate the efficacy and safety of rasagiline tablets in the treatment of Parkinson’s disease patients through UPDRSIII and UPDRSII scales,and evaluated the efficacy and safety of rasagiline tablets in the treatment of Parkinson’s disease patients.Results:A total of 3560 patients were included in this study.44.1%of patients had early Parkinson’s disease,52.4%had intermediate Parkinson’s disease,and 3.5%had advanced Parkinson’s disease.The UPDRSIII(exercise capacity)score was 26.76 at baseline,25.47 at 1 month,24.18 at 2 months,and 23.39 at 3 months after treatment,and scores significantly improved over time(P<0.001).The UPDRSII(ability to perform daily living)score was an average of 23.60 at baseline,22.49 at 1 month,21.53 at 2 months,and 21.09 at 3 months after treatment,with statistically significant differences in scores between months(P<0.001).A total of 18 adverse events/reactions occurred in this study,and adverse symptoms eventually disappeared or resolved,without termination due to adverse events/reactions or patient discharge.Conclusion:Rasagiline tablets have significant efficacy in improving daily exercise capacity and living ability in patients with Parkinson’s disease,and have a certain safety,which supports the effectiveness of rasagiline as a treatment for Parkinson’s disease and provides new evidence for its clinical application. 展开更多
关键词 Parkinson’s disease Rasagiline tablets UPDRS score
暂未订购
Application of Shexiang Baoxin Pill Combined with Rosuvastatin Calcium Tablets in the Treatment of Angina Pectoris due to Coronary Atherosclerotic Heart Disease
12
作者 Jingjiao Hui 《Journal of Clinical and Nursing Research》 2025年第11期230-236,共7页
Objective:To analyze the therapeutic efficacy of Shexiang Baoxin Pill combined with Rosuvastatin Calcium Tablets(ROS)in patients with angina pectoris due to coronary atherosclerotic heart disease(CHD-AP).Methods:Eight... Objective:To analyze the therapeutic efficacy of Shexiang Baoxin Pill combined with Rosuvastatin Calcium Tablets(ROS)in patients with angina pectoris due to coronary atherosclerotic heart disease(CHD-AP).Methods:Eighty CHD-AP patients admitted for treatment from January 2023 to December 2024 were selected and evenly divided using a random number table.The combined group(40 cases)received treatment with Shexiang Baoxin Pill combined with ROS,while the reference group(40 cases)received ROS monotherapy.The overall response rate,frequency and duration of AP attacks,blood lipid levels,and cardiac function indicators were compared between the two groups.Results:The combined group exhibited a higher overall response rate than the reference group.After treatment,the frequency and duration of AP attacks were lower in the combined group than in the reference group.Additionally,blood lipid levels and cardiac function indicators were superior in the combined group(p<0.05).Conclusion:The combination of Shexiang Baoxin Pill and ROS demonstrates favorable therapeutic effects in CHD-AP patients,effectively preventing AP attacks,regulating blood lipid levels,protecting cardiac function,and reducing disease risk. 展开更多
关键词 Shexiang Baoxin pill Rosuvastatin calcium tablets Coronary atherosclerotic heart disease Angina Pectoris
暂未订购
Pharmacokinetics of Controlled Release and Immediate Release Morphine Sulphate Tablets after a Single Dose and Multiple Doses in Chinese Volunteers
13
作者 邓艳萍 王凯 +3 位作者 刘立京 刘静雯 蔡志基 楼雅卿 《Journal of Chinese Pharmaceutical Sciences》 CAS 1997年第4期39-42,共4页
The pharmacokinetics of morphine sulphate was studied in 10 Chinese healthy volunteers after a single oral dose. Blood samples were collected before and after administration of controlled release tablets (CRMS, 30 mg)... The pharmacokinetics of morphine sulphate was studied in 10 Chinese healthy volunteers after a single oral dose. Blood samples were collected before and after administration of controlled release tablets (CRMS, 30 mg) and immediate release tablets (IRMS, 20 mg). The plasma concentration of morphine was determined by GC MS. The pharmacokinetic parameters of controlled release tablets and immediate release tablets were calculated∶ C max was 19.38±3.80 and 21.27±6.21 ng/ml, t max was 2.36 ±0.37 h and 0.56±0.16 h, t 1/2β was 3.53±0.87 and 3.03±0.74 h, AUC was 145.15±17.65 and 93.08±16.65 ng/ml, respectively. The steady state plasma concentration of morphine sulphate in cancer patients after multiple doses was achieved, C max of CRMS and IRMS was 27.43±0.33 ng/ml and 22.68±0.16 ng/ml, C min of CRMS and IRMS was 19.45±1.44 ng/ml and 18.14±0.49 ng/ml, respectively. 展开更多
关键词 Controlled release morphine sulphate tablet Immediate release morphine sulphate tablet PHARMACOKINETICS Single dose Multiple doses GC MS
全文增补中
Lappaconitine solid dispersion monolithic osmotic tablet and lappaconitine push-pull osmotic pump: preparation and comparison of their release performance in vitro 被引量:4
14
作者 吴先闯 王姣姣 +4 位作者 郝海军 宋晓勇 张永州 刘瑜新 张红芹 《Journal of Chinese Pharmaceutical Sciences》 CAS CSCD 2017年第6期413-422,共10页
Lappaconitine is a water-insoluble drug, which was used as model drug in this study. Currently, two osmotically controlled delivery systems that are widely used for water-insoluble drug are monolithic osmotic tablet ... Lappaconitine is a water-insoluble drug, which was used as model drug in this study. Currently, two osmotically controlled delivery systems that are widely used for water-insoluble drug are monolithic osmotic tablet (MOT) and push-pull osmotic pump (PPOP). In the present study, lappaconitine solid dispersion monolithic osmotic tablet (lappaconitine-SD-MOT) and lappaconitine-PPOP were developed. The prepared lappaconitine-PPOP was able to delivery drug at the rate of approximate zero-order (r = 0.9931), and the cumulative release was above 95.0%. The lappaconitine-SD-MOT showed a comparatively poor linearity when the data were plotted according to the zero-order equation (r = 0.9798), and the cumulative release was 84.69%. Lappaconitine-PPOP exhibited better controlled drug release (higher regression value) compared with lappaconitine-SD-MOT. The similarity index (f2) between lappaconitine-PPOP and lappaconitine-SD-MOT was 49.1 (〈50). A clear difference of drug release characteristics between the lappaconitine-SD-MOT and lappaconitine-PPOP was revealed. It indicated that the drug release performance of lappaconitine-PPOP could gain favorable zero-order kinetics and higher cumulative release compared with lappaconitine-SD-MOT. Therefore, these results suggested that PPOP was still a very effective device for the delivery of poorly water-soluble drug with zero-order pattern. 展开更多
关键词 LAPPACONITINE Solid dispersion Monolithic osmotic tablet Push-pull osmotic pumps
原文传递
Simultaneous Determination of Baicalin, Berberine and Rhein by HPLC in Traditional Chinese Patent Medicine Sanhuang Tablets 被引量:5
15
作者 李奕 高建平 许旭 《Journal of Chinese Pharmaceutical Sciences》 CAS 2005年第2期110-114,共5页
Aim To establish a reversed phase liquid chromatographic method forsimultaneous determination of three main medicinal constituents, baicalin, berberine and rhein, inSanhuang tablets. Methods The separation was perform... Aim To establish a reversed phase liquid chromatographic method forsimultaneous determination of three main medicinal constituents, baicalin, berberine and rhein, inSanhuang tablets. Methods The separation was performed on a Kromasil C_(18) column with TEA-adjusted0.02 mol·L^(-1) H_3PO_4 (pH 6.78)-acetonitrile-methanol (40 : 9 : 7) as mobile phase at aflow-rate of 1.0 mL·min^(-1), with detection at 254 ran. Considering interaction between acidic andalkaline compounds, three standard markers were added respectively and the volume of samplesolution was doubled in recovery experiments. Results Three regression equations revealed excellentlinear relationship between the peak areas and concentrations and the correlation coefficients allsurpassed 0.999 8. The average recovery was 96.1% (RSD = 2.1%) baicalin, 98.5% (RSD = 2.4%) forberberine, and 101.5% (RSD =1.3%) for rhein. Conclusion The method developed can be used to controlthe quality of Sanhuang tablets comprehensively. 展开更多
关键词 sanhuang tablets BAICALIN RHEIN BERBERINE HPLC
暂未订购
Preparation of monolithic osmotic tablet of quercetin loaded by solid dispersion 被引量:3
16
作者 郝海军 贾幼智 +4 位作者 张红芹 韩茹 王雪萍 韩丽妹 王建新 《Journal of Chinese Pharmaceutical Sciences》 CAS CSCD 2015年第6期383-392,共10页
The objective of this study was to prepare monolithic osmotic tablet of quercetin for controlled drug release. Quercetin-PVP solid dispersion was prepared to enhance its solubility and dissolution rate. Solid dispersi... The objective of this study was to prepare monolithic osmotic tablet of quercetin for controlled drug release. Quercetin-PVP solid dispersion was prepared to enhance its solubility and dissolution rate. Solid dispersion, suspending agents, osmotic agents and other conventional excipients were used as tablet core composition and cellulose acetate (CA) with plasticizer as release controlling membrane. Different formulation variables, the amounts of PEO (polyethylene oxide), NaC1, plasticizer, and coating weight gain were optimized to gain the optimum formulation. The mechanism of drug release from monolithic osmotic tablet was also discussed. The optimal monolithic osmotic pump tablet could deliver quercetin at the rate of approximate zero-order up to 12 h, and the cumulative release was 90.74%. The developed monolithic osmotic system for quercetin loaded by solid dispersion was found to be a promising approach for controlled release of poorly-water soluble drug candidates. 展开更多
关键词 QUERCETIN Solid dispersion Monolithic osmotic tablet Controlled drug delivery system
原文传递
Pharmacokinetics of nifedipine sustained-release tablets in healthy Chinese volunteers 被引量:3
17
作者 武静 王本杰 +2 位作者 魏春敏 卜凡龙 郭瑞臣 《Journal of Chinese Pharmaceutical Sciences》 CAS 2007年第3期192-196,共5页
Aim To establish a LC-MS method for determining the concentration of nifedipine in human plasma and to evaluate the pharmacokinetic characteristics of nifedipine sustained-release tablets. Methods A XB-C18 (5 μm, 4.... Aim To establish a LC-MS method for determining the concentration of nifedipine in human plasma and to evaluate the pharmacokinetic characteristics of nifedipine sustained-release tablets. Methods A XB-C18 (5 μm, 4.6 mm ×150 mm) column and a mobile phase of methanol: 0.01 mol·L^-1ammonium acetate (60:40, V/V) were used to separate nifedipine, the detections was accuracy under atmosperic pressure electronic spray ionization (AP-ESI) mode and ion mass spectrum (m/z) of 314.9 [M+H]^+ for nifedipine, and 320.8 [M+H]^+ for lorazepam (Internal Standard, IS). Results The linear range of nifedipine was 0.3 - 80 ng·mL^-1 ( r = 0.9997), and the limit of quantitation (LOQ) was 0.3 ng·mL^-1. The nifedipine pharmacokinetic parameters after a single dose of 20 mg nifedipine sustained-release tablets test (T) or reference (R) were as the followings, t1/2 (6.73 ± 2.00) h and (7.04 ± 2.18) h, Tmax (4.28 ± 0.70) h and (4.48 ± 0.70) h, Cmax(39.66 ± 10.58) ng·mL^-1 and (40.19 ± 10.97) ng·mL^-1, AUC0-36 (391.63 ± 108.55) ng·mL^-1·h and (387.57 ± 121.51) ng·mL^-1·h, and AUC0-∞ (408.28 ± 121.16) ng·mL^-1·h and (406.15 ± 133.13) ng·mL^-1·h. The relative bioavailability of nifedipine sustained-release tablets (test) was (103.02 ± 13.93) %. Conclusion LC-MS method for the determination of concentrations of nifedipine in human plasma was sensitive and accurate, and could be used in nifedipine bioavailability and pharmacokinetic studies. 展开更多
关键词 Nifedipine sustained-release tablets LC-MS PHARMACOKINETICS BIOEQUIVALENCE
暂未订购
Pharmacokinetics and Absolute Bioavailability of the Sublingual Naloxone Hydrochloride Tablet in Dogs 被引量:2
18
作者 葛召恒 李桦 +1 位作者 王宁 粱金度 《Journal of Chinese Pharmaceutical Sciences》 CAS 1996年第3期147-149,共3页
The pharmacokinetics and absolute bioavailability of the sublingual naloxone tablet were studied with HPLC-electrochemical detection. Eight male dogs received single 5 mg dose of naloxone intravenously, the plasma con... The pharmacokinetics and absolute bioavailability of the sublingual naloxone tablet were studied with HPLC-electrochemical detection. Eight male dogs received single 5 mg dose of naloxone intravenously, the plasma concentration-time curves could be fitted to two-compartment open model, with 12.0 min of t1/2( , 143.4 min of t1/2( and 7.92 mg(min/L of AUC. The same eight dogs received 5 mg dose of the sublingual naloxone tablet after an interval of a week. The main pharmacokinetic parameters were: t1/2ka = 11.0 min, t1/2( = 15.4 min, t1/2( = 164.1 min, Tmax = 27.7 min, Cmax = 34.2 ng / ml, and AUC = 6.79 mg(min / L, respectively. The plasma concentration-time curves were fitted to the first order absorption two-compartment open model also. The mean absolute bioavailability of the sublingual naloxone tablet was 86.8 ( 10.9%. No statistically significant differences were found with t1/2(, t1/2(, ( and ( between the two routes of administration. These results indicated that the course of disposition for naloxone in dogs was similar for the two routes of administration, and the absolute bioavailability of the sublingual naloxone tablet was high. Thus satisfactory clinical effects could be expected. 展开更多
关键词 NALOXONE Sublingual tablet BIOAVAILABILITY DOG HPLC-ED
暂未订购
Optimization and characterization of nimesulide bilayer tablets by response surface methodology 被引量:1
19
作者 单利 范云周 +3 位作者 王玉丽 陈红鸽 高春生 杨美燕 《Journal of Chinese Pharmaceutical Sciences》 CAS CSCD 2014年第2期89-93,共5页
The objectives of this present investigation were to develop and formulate nimesulide bilayer tablets by using different polymer combinations and fillers, to optimize the formulations for different drug release variab... The objectives of this present investigation were to develop and formulate nimesulide bilayer tablets by using different polymer combinations and fillers, to optimize the formulations for different drug release variables by orthogonal design and central composite design-surface methodology and to evaluate drug release pattern of the optimized product. The bilayer tablet containing a fast release layer(FRL) and a sustained release layer(SRL) provided an initial burst release of nimesulide, followed by the sustained release for a period of time. The optimal formulation obtained was as follows:(I) the formulation of FRL: nimesulide, 50 mg; lactose, 92 mg; starch, 22 mg; CCMC-Na, 14 mg; PVP K30, 1 mg; micronized silica gel, 1 mg; magnesium stearate, 0.9 mg; and iron oxide red, 0.1 mg; and(II) the formulation of SRL: nimesulide, 150 mg; HPMC K100LV, 26 mg; HPMC K4M, 33 mg; lactose, 54 mg; PVP K30, 1 mg; micronized silica gel, 1 mg; and magnesium stearate, 0.9 mg. According to the optimal formulation, the biphasic type of release was identified. The in vitro drug dissolution from the bilayer tablets was sustained for about 16 h after releasing 15% of drug in the first 10 min. The developed nimesulide bilayer tablets with improved efficacy can perform therapeutically better than the conventional tablets. 展开更多
关键词 NIMESULIDE Bilayer tablets Orthogonal design Central composite design-response surface methodology Sustainedrelease Fast release
原文传递
High Resolution Determination of Ondansetron in Human Plasma by HPLC and Pharmacokinetics of Orally Disintegrating Tablets 被引量:1
20
作者 陈伟 吴伟 +4 位作者 汪杨 黄敏 阙俐 胡弢 孙宁云 《Journal of Chinese Pharmaceutical Sciences》 CAS 2005年第3期162-168,共7页
Ahn To develop a high resolution HPLC method for the determination of ondansetron in human plasma and to study the pharmacokinetics of ondansetron in orally disintegrating tablets. Methods HPLC determination involved ... Ahn To develop a high resolution HPLC method for the determination of ondansetron in human plasma and to study the pharmacokinetics of ondansetron in orally disintegrating tablets. Methods HPLC determination involved liquid-liquid extraction, separation on a CN column and ultraviolet detection at 310 ran with granisetron as an internal standard. Pharmacokinetics and bioequivalence of ondansetron in orally disintegrating tablets by direct compression and conventional 8 mg tablets were evaluated and compared in 20 healthy human male volunteers after a single oral dose in a randomized cross-over study. Results The limit of quantification was 0.25 ng· mL^-1. The recovery was about 85 % or over for ondan setron and about 90% for internal standard. Linearity was good within the concentration range of 0.5 - 50 ng·mL^-1 with r^2 ranging from 0.997 1 to 0.999 9. Intra- and inter-assay coefficients of variation ranged from 1.78% to 2.38% and 3.88% -5.19%, respectively. Accuracies for spiked concentrations of 2.0, 10.0, and 30.0 ng·mL^-1 were 104.7% ±4.4%, 102.2% ± 1.1%, and99.51% ±2.34%, respectively. Pharmacokinetic parameters of AUCo-t, AUCo-∞ , Cmax, Tmax, and T1/2 were 230.2 ± 78.0 ng·h·L^-1 , 265.2± 101.5 ng·h·mL^-1, 35.67 ± 8.94 ng·mL^-l, 1.51 ±0.79 h, and 5.00± 1.41 h for orally disintegrating tablets, respectively. The analysis of variance did not show any significant difference between orally disintegrating tablets and conventional tablets, and 90% confidence intervals fell within the acceptable range for bioequivalence. Conclusion High resolution HPLC method has been set up and applied in pharmacokinetic evaluation of ondansetron in orally disintegrating tablets. 展开更多
关键词 ONDANSETRON HPLC orally disintegrating tablets PHARMACOKINETICS
暂未订购
上一页 1 2 250 下一页 到第
使用帮助 返回顶部